BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
April 11, 2007
View Archived Issues
Affimed Raises $33.5M For TandAbs In Oncology
Affimed Therapeutics AG raised €25 million (US$33.5 million) in a Series B round to fund its two lead programs, in non-Hodgkins lymphoma (NHL) and Hodgkin's disease. Each is in preclinical development at present. (BioWorld International)
Read More
Stem Cells Sciences Raises $9.9M With New ASX Listing
Read More
Innate Immunity, New Combo Of Antibiotics Fight Resistance
Read More
Patients' Group Voices Anger At Advanced Therapies Tactic
Read More
Atlantic Closes First Deal, Licensing GI Compound
Read More
Nokad Obtains Its First Functional KOs in Rats
Read More
Other News To Note
Read More